Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
about
Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3AImportance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataEffects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionThe influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review.Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceInduction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal modelsPharmacology and clinical use of voriconazole.Interactions between antifungal and antiretroviral agents.Pharmacogenomics of the triazole antifungal agent voriconazole.Update on the optimal use of voriconazole for invasive fungal infections.Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics.Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteersLong-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis.Pharmacokinetic interaction between efavirenz and ketoconazole in rats.Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis.Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients
P2860
Q24317436-26DA8E32-3494-432F-BF6A-3214B1AAE732Q27009128-58F25D32-BFEA-4B3A-AEC0-EEBCAB51A5D5Q33668215-B026AA27-A80B-4C13-B922-06D285B6E79BQ33821729-6B786E6E-4CE5-492E-BA9F-A12EDD505BACQ34116690-45CE26C6-BE23-4739-BAB1-F134D54BEFF0Q34976284-BCC23C1C-CF5C-47BD-9FC7-3ED9F924F885Q36273788-F42C6888-2BDD-47D0-944A-F283FA49C4A4Q36652680-F5FD77F7-75B5-4398-B007-44544F386CACQ36657589-ADA9D7EA-B729-4491-B3AF-98D54A7CEA63Q36887128-56A60AE6-6B50-4990-A61F-9F5F80962EA4Q36969849-156D2EF9-F5C6-418A-9BBC-8DE95C4395E3Q37126489-7F6B3295-D034-4B03-8CB9-659F7CAB3F98Q37358704-C2C2B1A6-3215-4335-A57B-FD00EC049AF4Q37378110-3910ED49-B711-4595-8145-294306CB5FABQ37395532-EAF70A7A-59D4-48AE-9769-9D0C72665206Q37641375-DA5C4143-70A5-4EE9-96B4-4C666CDF0EC4Q37719545-47E94C28-B140-43E9-9DD5-178142AC1574Q37892536-841D4EC8-6126-4230-8D99-F0FFB20E6113Q37892901-2959A817-5793-468E-A557-81464376B6C3Q37945308-2911F289-8EDA-42F9-B422-EC56931554CDQ38076073-781B73B2-3548-4BCE-9842-994121600C2EQ42272330-DE70F5CF-7C80-4BCF-BA8F-E8832264015AQ42283777-7090FD63-5FCE-41C4-96B5-78521E266AAEQ46041840-6B239F9B-A773-4048-B93F-D4CC9CE2BDE8Q46102614-D1DDDF34-3139-42B4-A518-5F4B0724B632Q46248271-AE4E30F2-5BAF-444B-8BCA-E7A1A19C8280Q47664190-10A32B6F-A878-45D3-9B4A-6A1C7960010DQ51631938-B7D0689D-70FC-4ED0-9F1E-A95B4A3D964EQ57611765-A9EB5FF1-E7D6-47B9-A8FE-F0FF0AFE888A
P2860
Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Pharmacokinetic interaction be ...... tate in healthy male subjects.
@en
Pharmacokinetic interaction be ...... tate in healthy male subjects.
@nl
type
label
Pharmacokinetic interaction be ...... tate in healthy male subjects.
@en
Pharmacokinetic interaction be ...... tate in healthy male subjects.
@nl
prefLabel
Pharmacokinetic interaction be ...... tate in healthy male subjects.
@en
Pharmacokinetic interaction be ...... tate in healthy male subjects.
@nl
P2093
P2860
P356
P1476
Pharmacokinetic interaction be ...... tate in healthy male subjects.
@en
P2093
Amarnath Sharma
Grover Foster
Maria J Gutierrez
Robert R LaBadie
P2860
P356
10.1177/0091270007309703
P577
2007-11-19T00:00:00Z